Kateřina Kopečková
A5036367652- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Renal cell carcinoma treatment
- Monoclonal and Polyclonal Antibodies Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Economic and Financial Impacts of Cancer
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Renal and related cancers
- Gastrointestinal Tumor Research and Treatment
- Cancer Treatment and Pharmacology
- Cardiac tumors and thrombi
- Cholesterol and Lipid Metabolism
- Ovarian cancer diagnosis and treatment
- Genetic factors in colorectal cancer
- Pharmacogenetics and Drug Metabolism
- Metastasis and carcinoma case studies
- Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Vascular Tumors and Angiosarcomas
- Drug Transport and Resistance Mechanisms
University Hospital in Motol
2016-2024
Charles University
2016-2024
University of Pisa
2024
Exelixis (United States)
2024
Eli Lilly (United Kingdom)
2024
Ipsen (France)
2024
AstraZeneca (Brazil)
2024
Eli Lilly (United States)
2024
Hospital de Sant Pau
2023
European Society for Medical Oncology
2018
Soft tissue sarcomas (STSs) gather over 80 histological entities, with even more molecular subsets, characterised by a low to very incidence in all populations. The majority of arise from the soft (close 75%), ∼15% gastrointestinal stromal tumours (GISTs) and 10% bone sarcomas. These ESMO–EURACAN (European Society for Medical Oncology–European Reference Network rare adult solid cancers) Clinical Practice Guidelines cover STSs, while GISTs are covered dedicated [1.Casali P.G. Abecassis N....
Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted incidence of around 1/100 000/year [1.Nilsson B. Bümming P. Meis-Kindblom J.M. et al.Gastrointestinal tumors: the incidence, prevalence, clinical course, and prognostication in preimatinib mesylate era–a population-based study western Sweden.Cancer. 2005; 103: 821-829Crossref PubMed Scopus (1027) Google Scholar]. This only covers clinically relevant GISTs, since, if investigated, a much higher number...
Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCARE (European Cancer Registry based study on survival and care cancer patients) database [1.Stiller C.A. Trama A. Serraino D. Descriptive epidemiology sarcomas Europe: report from RARECARE project.Eur J Cancer. 2013; 49: 684-695Abstract Full Text PDF PubMed Scopus (265) Google Scholar]. Different tumour subtypes have distinct patterns incidence, each has no more than 0.3 incident cases per 100...
Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in advanced RET-mutant medullary thyroid cancer phase 1–2 trial, but its as compared with approved multikinase inhibitors is unclear. Download PDF of the Research Summary. We conducted 3, randomized trial comparing selpercatinib first-line therapy physician's choice cabozantinib or vandetanib (control group). Eligible patients had progressive disease documented within 14 months before enrollment. The primary end...
The standard definition of 'rare cancer' is a malignant disorder with an incidence <6 per 100 000 year according to the Surveillance Rare Cancers in Europe (RARECARE), wide variety for different rare cancers.
Anti-CD19 immunotherapy tafasitamab is used in combination with lenalidomide patients relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant. Open-label, phase 1b, First-MIND study assessed safety and preliminary efficacy of + R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) ± as first-line therapy DLBCL. From December 2019 to August 2020, 83 adults untreated DLBCL (International Prognostic Index 2-5) were...
Post-hoc analyses of AFP response and progression their relationship with objective measures survival were performed in patients from REACH.Serum was measured at baseline every 3 cycles (2 weeks/cycle). Associations between radiographic efficacy end points analysed.Median percent increase smaller the ramucirumab than placebo arm throughout treatment. Time to (HR 0.621; P < 0.0001) 0.613; favoured ramucirumab. Association shown 6 (OR 6.44, 95% CI 4.03, 10.29; 12 weeks 2.28, 1.47, 3.53; =...
Abstract Background There is a steady decline in cancer mortality Western Europe (WE), but this trend not so obvious Central and Eastern (CEE). One of the largest discrepancies between WE CEE level investment care. The objective our analysis was to examine correlation mortality-to-incidence (M/I) ratio expenditures on oncology drugs WE. Materials Methods This cross-sectional done publicly available data. Data for were obtained from QuintilesIMS, data M/I Globocan. main outcome ratio, primary...
Breast cancer is the most common in women world. The role of germline genetic variability ATP-binding cassette (ABC) transporters chemoresistance and prognosis still needs to be elucidated. We used next-generation sequencing assess associations variants coding regulatory sequences all human ABC genes with response patients neoadjuvant cytotoxic chemotherapy disease-free survival (n = 105). A total 43 prioritized associating or above testing phase were then analyzed by allelic discrimination...
Olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, is partially hepatically cleared. We investigated the pharmacokinetics (PK) and safety of olaparib in patients with mild or moderate hepatic impairment to provide dosing recommendations.This Phase I open-label study assessed PK, tolerability single doses 300-mg tablets advanced solid tumours. Patients had normal function (NHF), (MiHI; Child-Pugh class A) (MoHI; B) impairment. Blood was collected for PK assessments 96 hours. could...
The metabolism of vandetanib, a tyrosine kinase inhibitor used for treatment symptomatic/progressive medullary thyroid cancer, was studied using human hepatic microsomes, recombinant cytochromes P450 (CYPs) and flavin-containing monooxygenases (FMOs). role CYPs FMOs in the microsomal vandetanib to N-desmethylvandetanib vandetanib-N-oxide investigated by examining effects CYP/FMO inhibitors correlating CYP-/FMO-catalytic activities each sample with amounts...
The Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of outcome metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at evaluation impact MSKCC score on outcomes in mRCC first-line sunitinib, a focus intermediate-risk group.Clinical 2390 were analysed retrospectively. Progression-free survival (PFS), overall (OS), and objective response rate (ORR)...